Repaglinide Krka 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
N/0019 
Minor change in labelling or package leaflet not 
13/12/2022 
connected with the SPC (Art. 61.3 Notification) 
N/0018 
Minor change in labelling or package leaflet not 
06/12/2021 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IA/0017 
B.II.b.4.b - Change in the batch size (including batch 
02/07/2021 
n/a 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IB/0016/G 
This was an application for a group of variations. 
28/10/2020 
19/10/2021 
SmPC, Annex 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
N/0015 
Minor change in labelling or package leaflet not 
27/10/2017 
19/10/2021 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0014 
B.II.d.2.a - Change in test procedure for the finished 
26/10/2017 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0013 
B.II.d.2.a - Change in test procedure for the finished 
28/07/2017 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0012/G 
This was an application for a group of variations. 
09/02/2017 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0011/G 
This was an application for a group of variations. 
28/06/2016 
16/02/2017 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0010 
B.III.1.a.2 - Submission of a new/updated or 
08/06/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0009 
A.5.a - Administrative change - Change in the name 
23/03/2016 
16/02/2017 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
R/0007 
Renewal of the marketing authorisation. 
26/06/2014 
22/08/2014 
This is a renewal of the Marketing Authorisation for a 
generic product.  
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0008 
B.III.1.a.3 - Submission of a new/updated or 
30/04/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IAIN/0006/G 
This was an application for a group of variations. 
18/12/2013 
22/08/2014 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
IA/0005/G 
This was an application for a group of variations. 
08/10/2013 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IAIN/0004 
B.III.1.a.3 - Submission of a new or updated Ph. Eur. 
08/03/2013 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
During the renewal period no significant information has 
arisen that alters the overall assessment of the benefit/risk 
balance of the product. 
The CHMP recommends that the renewal be granted with 
unlimited validity. 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monograph - New certificate from a new 
manufacturer (replacement or addition) 
IB/0003/G 
This was an application for a group of variations. 
26/07/2012 
n/a 
SmPC, Annex 
II, Labelling 
and PL 
Updated section 4.5 of the SmPC in order to include 
a new drug-drug interaction with deferasirox. Section 
2 of the Package Leaflet has been updated 
accordingly. 
The Product Information has also been updated in 
line with the latest QRD template (version 8). 
The MAH took this opportunity to harmonise the text 
with the originator to include a new indication, which 
is already approved for the reference product.  
All changes have been made in order to harmonise 
the text with the originator. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0002 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
05/07/2012 
n/a 
SmPC, Annex 
life of the finished product - As packaged for sale 
II and PL 
(supported by real time data) 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
22/05/2012 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
